Pharmasset, Inc.

Takeda Pharmaceutical Co. Ltd. will go after Bristol Myers Squibb Company and its recently approved oral TYK2 inhibitor Sotyktu for moderate-to-severe psoriasis, agreeing on 13 December to pay Nim

Apparently sourcing your experimental drug from the platform behind a mega-blockbuster will attract significant investor interest, as Antios Therapeutics Inc. demonstrated with a $96m series B finan

Atea Pharmaceuticals Inc. has been quietly developing a pipeline of oral direct-acting antiviral drugs against hepatitis C and other RNA viruses since 2014, but now the company has emerged from steal

Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin. As earni